Long COVID SymptomsPERSICOV-19NCT07417176
Persistent COVID-19 Registry in Navarre.
An observational study of Long COVID Symptoms and Long COVI, run by Fundacion Miguel Servet at 1 site in Spain.
Trial summary
The goal of this observational study is to deepen our understanding of long COVID by determining the prevalence of the main complications and medium- to long-term sequelae of COVID-19 in Navarre. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Long COVID Symptoms, Long COVI
- How many people
- 200 participants
- Where
- 1 siteSpain
- Study dates
- 4 Jan 2021to 31 Mar 2026
- How long will I take part?
- 3 Months
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Patients seen in the Internal Medicine outpatient clinic who have been referred by primary care teams or other medical services.
Who may be able to join
- History of confirmed SARS-CoV-2 infection
- Presentation of symptoms that have persisted for more than 3 months after SARS-CoV-2 infection
- The patient reports any of the symptoms listed in the clinical assessment questionnaire or checklist.
Who cannot join
- The symptom(s) referred to already existed prior to acute SARS-CoV-2 infection.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Spain1 site, 1 recruiting
- Recruiting
Hospital Universitario de Navarra
Pamplona, Navarre, 31008
Patricia Fanlo Mateo., MD, PhD, +34639668497, patricia.fanlo.mateo@navarra.es
Patricia Fanlo Mateo, MD, PhD
About this study
Official title: Persistent COVID-19 Registry in Navarre. (Persicov-19)
The goal of this observational study is to deepen our understanding of long COVID by determining the prevalence of the main complications and medium- to long-term sequelae of COVID-19 in Navarre.
Sociodemographic variables such as age, sex, ethnicity, smoking history, and comorbidities will be collected, as well as clinical and disease management variables such as persistent COVID-19 symptoms at 3 months, all with the aim of characterizing patients with long COVID.
All patient data will be collected in a single visit.
Read the detailed description
COVID-19 is the largest pandemic faced by the public health system in the last hundred years. The medium- and long-term consequences of SARS-COV-2 infection are currently unknown. Studies on coronavirus-induced lung damage in previous epidemics such as SARS-CoV and MERS-CoV have shown an increase in morbidity and mortality due to pulmonary fibrosis as a consequence of adult respiratory distress syndrome (ARDS) caused by these viruses. COVID-19 has also been shown to be a multisystemic disease with the potential to affect multiple organs or systems, damaged directly by the virus and/or indirectly by a dysfunctional immune response and/or by the supportive therapies used.
The healthcare system is currently focusing on the acute care of this disease, but continuous monitoring of these patients is necessary since many of them continue to have symptoms after the acute phase of the disease, known as persistent COVID-19 or long COVID. Long COVID or persistent COVID is the term used to describe the disease in people who have recovered from the disease but still report lasting effects from the infection or who have symptoms for longer than would be expected².
The study published by Carfi et al, conducted in a hospital in Rome, has shown that 9 out of 10 patients (87%) who had been discharged from hospital with COVID-19 60 days after discharge still reported at least one symptom of COVID-19³.
The investigators believe that once this peak phase of the epidemic has passed, it is very important to monitor the progress of patients who have suffered a moderate or severe infection in order to assess the presence of complications in the medium and short term. For this reason, it is necessary to implement a coordinated care protocol for patients diagnosed with persistent COVID-19 or with sequelae, involving both primary and hospital care, with a specific monographic consultation, as has been done in other centres⁴ and as agreed between the Spanish Society of Internal Medicine (SEMI) and the Spanish Society of Primary Care Physicians (SEMERGEN)⁵.
The establishment of a specific care pathway for persistent COVID patients, together with the creation of a registry of these patients that collects information on their demographic and clinical characteristics, will make it possible to determine the prevalence of complications in this population and will provide the infrastructure and basis necessary for carrying out future short- to medium-term clinical projects aimed at the prevention and treatment of persistent COVID disease in Navarra.
The overall objective of this project is to deepen our understanding of persistent COVID disease in our environment. This overall objective will be carried out in accordance with the following specific objectives:
- Establish an effective and coordinated care pathway between primary care and hospital care specifically for persistent COVID patients, facilitating comprehensive care and follow-up while avoiding duplication and overlap of consultations.
- Generate a registry of patients with persistent COVID-19 in Navarre (PersiCOV-19) through the prospective collection of sociodemographic, clinical, and analytical information on these patients.
- Describe the demographic, clinical, and analytical characteristics of patients with persistent COVID in our setting.
- Establish the prevalence of different symptoms, complications and/or medium- to long-term sequelae of COVID-19 in Navarre.
- Record the use of the different therapeutic options used to prevent and/or treat potential complications.
- Analyse the possible factors that condition the presence of certain complications.
The work plan is as follows:
Register patients seen in outpatient consultations at the Internal Medicine Department of the Navarra Hospital Complex who have been referred from Primary Care, from the Internal Medicine Department of the Navarra Hospital Complex itself, or from other departments.
Patient registration will begin in January 2021 and end in December 2026. Patients assessed by Primary Care Teams (Primary Care Physician or Case Management Nurse) who present symptoms compatible with persistent Covid will be referred to the Internal Medicine clinic.
Patients who have been assessed in outpatient clinics by professionals from other specialities and who present symptoms compatible with persistent Covid will be referred to the Internal Medicine clinic.
It is recommended that patients undergo the following procedures before referral:
- a clinical assessment questionnaire (Annex 1), which may be conducted by telephone and/or in person
- a blood test including a complete blood count, coagulation, CRP, ferritin, LDH, liver and kidney profile
- a chest X-ray.
If they do not have these, they will be carried out at the Internal Medicine clinic.
If the symptoms are debilitating and prevent the patient from carrying out an active working and daily life, they may be referred to the Internal Medicine clinic on a priority basis within 3 months.
This study is an observational, descriptive, cross-sectional, prospective cohort study that will include patients seen in the outpatient clinic of the Internal Medicine department who have been referred from primary care teams or other departments.
The sociodemographic and clinical characteristics of the study population and the treatments received will be described using descriptive statistics such as mean and standard deviation or median and interquartile range for continuous variables, depending on their nature, and frequencies and percentages for categorical variables. The prevalence of certain complications and sequelae in this population will be estimated using frequencies and their 95% CI. If any comparisons are made between patients with certain complications, these will be performed using parametric techniques such as Student's t-test or non-parametric techniques such as Mann-Whitney's U test for quantitative variables and the Chi-square test or Fisher's test for qualitative variables. Data analysis will be performed using statistical programmes such as the free software R 4.0.2 or IBM SPSS Statistics 21.
The fact that the registry is an observational study of a single cohort of patients with persistent COVID (without a comparison group) will have limitations in that it will not be possible to establish risk factors or possible causes related to the development of persistent COVID, and the investigators may encounter biases such as sample selection and recall bias.
- Conditions
- Long COVID Symptoms, Long COVI
- Keywords
- long covid 19, Long COVID syndrome, Long COVID Fatigue
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Patients diagnosed with long COVID | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Describe the demographic, clinical and analytical characteristics of patients with persistent COVID in our setting.
The following sociodemographic variables: age, gender, ethnicity, smoking history, and comorbidities, and analytical variables, will be collected.
Measured: Basal visit
Establish the prevalence of different symptoms, complications and/or medium- to long-term sequelae of COVID-19 in Navarre.
- Diagnosis of:
- Thromboembolic disease (deep vein thrombosis and/or pulmonary embolism at discharge and/or pulmonary thromboembolism).
- Acute cerebrovascular accident (embolic and/or atherothrombotic: referred to as stroke/ACVA/TIA/cerebral infarction) during admission for COVID-19. Establish assessment criteria by Internal Medicine and/or Neurology.
- Peripheral arterial ischaemic event during admission for COVID-19
- Acute complication of pre-existing coronary artery disease and/or acute coronary event (acute coronary syndrome or ACS).
- suspicion and/or diagnosis of myopericarditis during admission.
- criteria for acute hepatitis (GOT and/or GPT >5 times normal range (>200 during admission) and/or liver dysfunction (Br >3 mg/dl).
Measured: Basal visit
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Feb 2026
- Study start4 Jan 2021
- Primary completion1 Mar 2026 (estimated)
- Study completion31 Mar 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Long COVID SymptomsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 200 participants (estimated)
- Target duration
- 3 Months
Sponsor and investigators
- Lead sponsor
- Fundacion Miguel Servet
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Patricia Fanlo Mateo, MD, PhD, Principal investigator, Hospital Universitario de Navarra. Pamplona. Spain
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07417176
- Sponsor's protocol ID
- PERSCOVCHN
- Acronym
- PERSICOV-19
- Status last verified
- Feb 2026
- First submitted
- 11 Feb 2026
- Last updated
- 20 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Persistent COVID-19 Registry in Navarre. (Persicov-19)
- ClinicalTrials.gov ID
- NCT07417176
- Acronym / sponsor ID
- PERSICOV-19 / PERSCOVCHN
- Conditions
- Long COVID Symptoms, Long COVI
- Keywords
- long covid 19, Long COVID syndrome, Long COVID Fatigue
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- Fundacion Miguel ServetUniversity, hospital or other
- Study start
- 4 Jan 2021 (actual)
- Primary completion
- 1 Mar 2026 (estimated)
- Study completion
- 31 Mar 2026 (estimated)
- First posted
- 18 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to deepen our understanding of long COVID by determining the prevalence of the main complications and medium- to long-term sequelae of COVID-19 in Navarre.
Sociodemographic variables such as age, sex, ethnicity, smoking history, and comorbidities will be collected, as well as clinical and disease management variables such as persistent COVID-19 symptoms at 3 months, all with the aim of characterizing patients with long COVID.
All patient data will be collected in a single visit.
Detailed description
COVID-19 is the largest pandemic faced by the public health system in the last hundred years. The medium- and long-term consequences of SARS-COV-2 infection are currently unknown. Studies on coronavirus-induced lung damage in previous epidemics such as SARS-CoV and MERS-CoV have shown an increase in morbidity and mortality due to pulmonary fibrosis as a consequence of adult respiratory distress syndrome (ARDS) caused by these viruses. COVID-19 has also been shown to be a multisystemic disease with the potential to affect multiple organs or systems, damaged directly by the virus and/or indirectly by a dysfunctional immune response and/or by the supportive therapies used.
The healthcare system is currently focusing on the acute care of this disease, but continuous monitoring of these patients is necessary since many of them continue to have symptoms after the acute phase of the disease, known as persistent COVID-19 or long COVID. Long COVID or persistent COVID is the term used to describe the disease in people who have recovered from the disease but still report lasting effects from the infection or who have symptoms for longer than would be expected².
The study published by Carfi et al, conducted in a hospital in Rome, has shown that 9 out of 10 patients (87%) who had been discharged from hospital with COVID-19 60 days after discharge still reported at least one symptom of COVID-19³.
The investigators believe that once this peak phase of the epidemic has passed, it is very important to monitor the progress of patients who have suffered a moderate or severe infection in order to assess the presence of complications in the medium and short term. For this reason, it is necessary to implement a coordinated care protocol for patients diagnosed with persistent COVID-19 or with sequelae, involving both primary and hospital care, with a specific monographic consultation, as has been done in other centres⁴ and as agreed between the Spanish Society of Internal Medicine (SEMI) and the Spanish Society of Primary Care Physicians (SEMERGEN)⁵.
The establishment of a specific care pathway for persistent COVID patients, together with the creation of a registry of these patients that collects information on their demographic and clinical characteristics, will make it possible to determine the prevalence of complications in this population and will provide the infrastructure and basis necessary for carrying out future short- to medium-term clinical projects aimed at the prevention and treatment of persistent COVID disease in Navarra.
The overall objective of this project is to deepen our understanding of persistent COVID disease in our environment. This overall objective will be carried out in accordance with the following specific objectives:
- Establish an effective and coordinated care pathway between primary care and hospital care specifically for persistent COVID patients, facilitating comprehensive care and follow-up while avoiding duplication and overlap of consultations.
- Generate a registry of patients with persistent COVID-19 in Navarre (PersiCOV-19) through the prospective collection of sociodemographic, clinical, and analytical information on these patients.
- Describe the demographic, clinical, and analytical characteristics of patients with persistent COVID in our setting.
- Establish the prevalence of different symptoms, complications and/or medium- to long-term sequelae of COVID-19 in Navarre.
- Record the use of the different therapeutic options used to prevent and/or treat potential complications.
- Analyse the possible factors that condition the presence of certain complications.
The work plan is as follows:
Register patients seen in outpatient consultations at the Internal Medicine Department of the Navarra Hospital Complex who have been referred from Primary Care, from the Internal Medicine Department of the Navarra Hospital Complex itself, or from other departments.
Patient registration will begin in January 2021 and end in December 2026. Patients assessed by Primary Care Teams (Primary Care Physician or Case Management Nurse) who present symptoms compatible with persistent Covid will be referred to the Internal Medicine clinic.
Patients who have been assessed in outpatient clinics by professionals from other specialities and who present symptoms compatible with persistent Covid will be referred to the Internal Medicine clinic.
It is recommended that patients undergo the following procedures before referral:
- a clinical assessment questionnaire (Annex 1), which may be conducted by telephone and/or in person
- a blood test including a complete blood count, coagulation, CRP, ferritin, LDH, liver and kidney profile
- a chest X-ray.
If they do not have these, they will be carried out at the Internal Medicine clinic.
If the symptoms are debilitating and prevent the patient from carrying out an active working and daily life, they may be referred to the Internal Medicine clinic on a priority basis within 3 months.
This study is an observational, descriptive, cross-sectional, prospective cohort study that will include patients seen in the outpatient clinic of the Internal Medicine department who have been referred from primary care teams or other departments.
The sociodemographic and clinical characteristics of the study population and the treatments received will be described using descriptive statistics such as mean and standard deviation or median and interquartile range for continuous variables, depending on their nature, and frequencies and percentages for categorical variables. The prevalence of certain complications and sequelae in this population will be estimated using frequencies and their 95% CI. If any comparisons are made between patients with certain complications, these will be performed using parametric techniques such as Student's t-test or non-parametric techniques such as Mann-Whitney's U test for quantitative variables and the Chi-square test or Fisher's test for qualitative variables. Data analysis will be performed using statistical programmes such as the free software R 4.0.2 or IBM SPSS Statistics 21.
The fact that the registry is an observational study of a single cohort of patients with persistent COVID (without a comparison group) will have limitations in that it will not be possible to establish risk factors or possible causes related to the development of persistent COVID, and the investigators may encounter biases such as sample selection and recall bias.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 3 Months
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients diagnosed with long COVID | – | – |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patients seen in the Internal Medicine outpatient clinic who have been referred by primary care teams or other medical services.
Key inclusion criteria (3 listed)
- History of confirmed SARS-CoV-2 infection
- Presentation of symptoms that have persisted for more than 3 months after SARS-CoV-2 infection
- The patient reports any of the symptoms listed in the clinical assessment questionnaire or checklist.
Key exclusion criteria (1 listed)
- The symptom(s) referred to already existed prior to acute SARS-CoV-2 infection.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Describe the demographic, clinical and analytical characteristics of patients with persistent COVID in our setting.
Time frame: Basal visit
The following sociodemographic variables: age, gender, ethnicity, smoking history, and comorbidities, and analytical variables, will be collected.
Establish the prevalence of different symptoms, complications and/or medium- to long-term sequelae of COVID-19 in Navarre.
Time frame: Basal visit
6) Diagnosis of: * Thromboembolic disease (deep vein thrombosis and/or pulmonary embolism at discharge and/or pulmonary thromboembolism). * Acute cerebrovascular accident (embolic and/or atherothrombotic: referred to as stroke/ACVA/TIA/cerebral infarction) during admission for COVID-19. Establish assessment criteria by Internal Medicine and/or Neurology. * Peripheral arterial ischaemic event during admission for COVID-19 * Acute complication of pre-existing coronary artery disease and/or acute coronary event (acute coronary syndrome or ACS). * suspicion and/or diagnosis of myopericarditis during admission. * criteria for acute hepatitis (GOT and/or GPT >5 times normal range (>200 during admission) and/or liver dysfunction (Br >3 mg/dl).
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Feb 2026.
- Individual participant dataSharing planned: No
Related trials for Long COVID Symptoms
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Enrolling by invitationPhase 2
Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2
Systemic Inflammation, Neuroinflammation
RecruitingPhase 2
DAOIB for the Treatment of Brain Fog
Long COVID
Active, not recruitingObservational study
Pain in Long COVID-19: The Role of Sleep
Long COVID
Recruiting
Effect of Hi-OxSR for the Treatment of Post COVID Condition
Long COVID, Post COVID-19 Condition
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Patricia Fanlo Mateo, MD, PhD principal investigator
Hospital Universitario de Navarra. Pamplona. Spain
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Long COVID Symptoms and Long COVI, run by Fundacion Miguel Servet at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 20 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ruth García Rey, SC (+3484822163, ruth.garcia.rey@navarra.es), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Describe the demographic, clinical and analytical characteristics of patients with persistent COVID in our setting. (time frame: Basal visit). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Feb 2026.